DYN$16.692.05%-0.35
Dyne Therapeutics Inc (DYN)
Date: 2026-10-30 16:00O: 16.97H: 17.20L: 16.34C: 16.69Vol: 1.450M
Dyne Therapeutics Inc stock is traded at $16.69, with a volume of 1,449,801. It is down -2.05% in the last 24 hours and up +3.60% over the past month. Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
Previous Close:
$17.04
Open:
$16.97
24h Volume:
1,449,801
Relative Volume:
0.64
Market Cap:
$3.12B
Revenue:
-
Net Income/Loss:
-$451.71M
P/E Ratio:
-
EPS:
-$3.23
Net Cash Flow:
-$462.19M
1W Performance:
+6.85%
1M Performance:
+3.60%
6M Performance:
-4.90%
1Y Performance:
-29.13%
1-Day Range:
$16.34$17.20
1-Week Range:
$15.53$17.59
52-Week Range:
$14.00$27.31
Dyne Therapeutics Inc Stock (DYN) Company Profile
Name
Dyne Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
(781) 786-8230Address
1560 TRAPELO ROAD, WALTHAM, USACompare DYN vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DYN Dyne Therapeutics Inc | $16.69 | $3.12B | $0 | -$451.71M | -$462.19M | -$3.23 |
 VRTX Vertex Pharmaceuticals Inc | $558.88 | $141.65B | $12.34B | $4.34B | $3.71B | $16.87 |
 REGN Regeneron Pharmaceuticals Inc | $927.89 | $95.53B | $14.92B | $4.42B | $3.79B | $41.04 |
 MRNA Moderna Inc | $221.72 | $88.52B | $2.23B | -$3.19B | -$1.60B | -$8.15 |
 ARGX Argen X Se Adr | $892.87 | $56.15B | $4.16B | $1.29B | $734.26M | $19.58 |
 ONC Beone Medicines Ltd Adr | $370.33 | $41.89B | $5.76B | $514.49M | $1.10B | $4.48 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
Dyne Therapeutics Inc Stock (DYN) Financials Data
Revenue
Chart is being upgraded
This chart will be back soon.
Net Income
Cash Flow
EPS
Dyne Therapeutics Inc Stock (DYN) Insider Trading
- Cox JohnSep 08 '26CEO & President
- Transaction
- Sale
- Cost
- $18.88
- #Shares
- 5,658
- Value ($)
- 106,823
- #Shares Total
- 357,507
- Cox JohnSep 08 '26Officer
- Transaction
- Proposed Sale
- Cost
- $18.88
- #Shares
- 5,658
- Value ($)
- 106,844
- #Shares Total
- 0
- Friedl-Naderer JohannaSep 08 '26Chief Commercial Officer
- Transaction
- Sale
- Cost
- $18.88
- #Shares
- 185
- Value ($)
- 3,493
- #Shares Total
- 152,897
- Kerr DouglasSep 08 '26Officer
- Transaction
- Proposed Sale
- Cost
- $18.89
- #Shares
- 35
- Value ($)
- 661
- #Shares Total
- 0
- Kerr DouglasSep 08 '26Chief Medical Officer
- Transaction
- Sale
- Cost
- $18.88
- #Shares
- 1,290
- Value ($)
- 24,355
- #Shares Total
- 162,564
- Kerr DouglasSep 04 '26Officer
- Transaction
- Proposed Sale
- Cost
- $24.35
- #Shares
- 5,000
- Value ($)
- 121,745
- #Shares Total
- 0
- Kerr DouglasSep 04 '26Chief Medical Officer
- Transaction
- Sale
- Cost
- $24.35
- #Shares
- 3,745
- Value ($)
- 91,191
- #Shares Total
- 163,854
- Friedl-Naderer JohannaSep 04 '26Chief Commercial Officer
- Transaction
- Sale
- Cost
- $24.35
- #Shares
- 900
- Value ($)
- 21,915
- #Shares Total
- 153,082
- Atlas Venture Opportunity FundAug 14 '26Shareholder
- Transaction
- Proposed Sale
- Cost
- $25.96
- #Shares
- 322,465
- Value ($)
- 8,371,191
- #Shares Total
- 0
- Rhodes Jason PAug 14 '26Director
- Transaction
- Sale
- Cost
- $25.00
- #Shares
- 2,160,516
- Value ($)
- 54,012,900
- #Shares Total
- 428,946
